title: [Curative effects of pulsed electromagnetic fields on postmenopausal osteoporosis].
abstract: We investigated the effects and optimal treatment frequency of pulsed electromagnetic fields (PEMFs) on postmenopausal osteoporosis (PMO). A comparison was performed with the cyclical alendronate and a course of PEMFs in the treatment for postmenopausal osteoporosis on bone mineral density (BMD), pain intensity and balance function. There was no significant difference between the two groups on mean percentage changes from baseline of BMD within 24 weeks after random treatments (P > or = 0.05). However, at the ends of 48 weeks and 72 weeks, the BMD of the PEMFs group were significantly lower than that of the alendronate group (P < 0.05). No significant difference was detected between the two groups with regard to treatment effects on Visual Analogue Scale score, the Timed Up & Go Test and Berg Balance Scale score. Compared with cyclical alendronate, a course of PEMFs was as effective as alendronate in treating PMO for at least 24 weeks. So its optimal treatment frequency for PMO may be one course per six months.
authors.forename: Huifang
authors.initials: H
authors.lastname: Liu
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.forename: Chunyan
authors.initials: C
authors.lastname: Wang
authors.forename: Yuanchao
authors.initials: Y
authors.lastname: Wu
authors.forename: Chengqi
authors.initials: C
authors.lastname: He
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004574:Electromagnetic Fields; D005260:Female; D006801:Humans; D055909:Magnetic Field Therapy; D015663:Osteoporosis, Postmenopausal / Q000628:therapy*
chemical_list: D050071:Bone Density Conservation Agents; D019386:Alendronate